POPULARITY
15 episodes with new treatments
7 episodes with new treatments
5 episodes with new treatments
4 episodes with new treatments
3 episodes with new treatments
2 episodes with new treatments
3 episodes with new treatments
4 episodes with new treatments
2 episodes with new treatments
In this episode of The Egg Whisperer Show, Dr. Jenna Turocy is joining me to talk about new treatment options for recurrent implantation failure. Recurrent implantation failure (RIF) is determined when embryos of good quality fail to implant following several in vitro fertilization (IVF) treatment cycles. The good news is that there is treatment for this, and Dr. Turocy has been researching it. The types of treatments that Dr. Jenna has studied include:
Live Greater | A University of Maryland Medical System Podcast
Learn how COPD treatment is changing, including newer medications, ways to prevent flare-ups, affordability tips and questions to ask your pulmonologist. Featuring Dr. Kathryn Robinett, a pulmonary critical care physician at UMMC Midtown Center for Pulmonary Health. For more information about Dr. Robinett
In this episode, host Jenn Dawson talks with Dr. Dawn Davis, Dr. Amy Paller, and Dr. Larry Eichenfield about the newly published pediatric atopic dermatitis guidelines and what they mean for clinicians, patients, and families. Together, they unpack the evidence behind prevention, comorbidities, and treatment recommendations, discuss how rapidly the therapeutic landscape is evolving, and highlight the biggest unanswered questions that remain in research. The conversation also explores the importance of patient advocacy, shared decision-making, and improving access to care as the field moves toward more personalized treatment.Guidelines of care for primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis.Guidelines of care for the management of atopic dermatitis in pediatric patients.Please click here for a list of speakers' conflicts of interest.
Send us Fan MailThis week, I'm joined by optometrist Dr. Dawn Wattenhofer for a conversation about dry eye, light sensitivity, and the surprising ways our modern lifestyle impacts eye health. We talk about how screen use, inflammation, and environmental stressors affect the eyes, why dry eye is becoming increasingly common, and what newer therapies are changing the way practitioners approach treatment. Dr. Dawn also shares how her perspective on sunlight and eye care has evolved over the years and why supporting long-term eye function requires a more whole-body approach.KEY TAKEAWAYS: • Your eyes need healthy blinking habits • Modern life is hard on eye health • Sunlight isn't always the enemy • New therapies are changing dry eye care • The eyes reflect what's happening in the bodyABOUT GUEST: Dr. Dawn Wattenhofer is co-owner of Vision Source Specialists in Rapid City and has practiced optometry since 1998. She specializes in dry eye testing and treatment through the clinic's Ocular Surface Disease Clinic and has completed extensive post-doctoral training focused on overall health, wellness, and their impact on the eyes. Dr. Wattenhofer has also completed specialized dry eye training through the Dry Eye Institute and Dry Eye University. WHERE TO FIND GUEST:Website: https://www.visionsourcespecialists.com/Instagram: https://www.instagram.com/sd_visionsource/Facebook: https://www.facebook.com/SDVisionSource/SPONSOR:Thank you to Jigsaw Health for being such a great sponsor.
A new treatment for those suffering from PTSD. The "gold-standard" treatments for Parkinson's disease may be working against each other. Do tv commercials actually work? The impact of being in a romantic relationship with a narcissist. Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this powerful crossover episode, Bethany Lewis (The Concussion Coach), a neurological occupational therapist and certified life coach, joins Bruce Parkman of the Broken Brains podcast to shatter common myths about concussions. Bethany explains that you don't need to be knocked out—or even hit your head—to sustain a concussion, and that the severity of the impact doesn't always predict the outcome. She discusses how concussions are often misdiagnosed as mental health issues (anxiety, depression, ADHD), the critical link between repetitive head impacts and long-term brain health, and how women and girls are more susceptible yet severely understudied. Bethany offers hope through neuroplasticity and whole-person recovery, while providing essential advice for parents: believe your child's symptoms, prioritize their brain over the sport, and advocate for proper care. This episode is a must-listen for athletes, parents, coaches, and anyone wanting to understand the true impact of a "silent injury."Connect with Bethany:Website: https://theconcussioncoach.com/Free Guide: "5 Best Ways to Support Your Loved One Dealing with a Concussion" on the websiteFree Coaching Consultation: https://theconcussioncoach.com/free-consultationEpisodes mentioned by Bethany:The Concussion Coach Podcast episode 124 with Dr. Kellianne Arnella: https://youtu.be/k7CbCVzjQNQThe Concussion Coach Podcast episode 96 with Natasha Wilch: https://youtu.be/9CDVMmmBpJIBethany Lewis on Concussions, Neuroplasticity & Protecting Kids from Brain Injury | Broken Brains Podcast Episode 88Bethany Lewis joins Bruce Parkman to discuss the realities of concussions, the dangers of repetitive brain trauma, and how parents can better protect their children.In This Episode, We Cover:Concussions and repetitive brain trauma Neuroplasticity and brain recovery Symptoms and warning signs of concussion Mental health and brain injury Advice for parents, coaches, and athletes Key Takeaways:Concussions are brain injuries, not “just headaches” Early awareness can improve recovery outcomes Neuroplasticity gives hope for healing Parents must prioritize brain health over sports performance Resources & Links:The Concussion Coach Head Smart App Repetitive Brain Trauma Summit
What is an EGFR mutation — and could you pass it down to your children? Patient advocate Lysa Buonanno asks the questions every EGFR-positive lung cancer patient wants answered. Dr. Alice Berger, a lung cancer researcher at Fred Hutch Cancer Center, explains how EGFR mutations develop, why they are rarely inherited, and what targeted treatments — including exciting new FDA-approved options — mean for patients today. Whether you are newly diagnosed or supporting a loved one, this conversation will help you understand your biomarker results, know what to ask your doctor, and feel empowered by the science moving forward on your behalf. Topics covered: · What EGFR mutations are and how they develop · Whether EGFR mutations can be passed to children · The role of family history and genetic testing · Risk factors including radon, pollution, and smoking · Targeted therapies like osimertinib (Tagrisso) · New FDA-approved treatments for EGFR exon 20 mutations · Ongoing research into hereditary lung cancer risk Guests: Lysa Buonanno, Patient Advocate Dr. Alice Berger, Associate Professor, Fred Hutch Cancer Center Show Notes - https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-EGFR-Positive-Lung-Cancer-Show-Notes.pdf Transcript - https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-EGFR-Positive-Lung-Cancer-Transcript.pdf Watch Video - https://youtu.be/izHAxxwZVL4 Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform. Join LCFA's social media communities for support and information. Facebook | Twitter | Instagram | YouTube
Scientists at Oregon Health & Science University’s Knight Cancer Institute are pioneering a new way to study cancer that could lead to faster cancer detection and more targeted treatment. It involves 3D printing cancer cells from a patient and miniature versions of organs like bones and lungs. The healthy tissue and cancer cells are placed together inside a tiny device that’s roughly the size of a thumbdrive. Scientists can then observe in real time how they interact and discover ways to halt the cancer’s spread into the healthy tissue. Luiz Bertassoni is the director of the institute’s Precision Biofabrication Hub, which he helped launch in 2023, and a professor of oncology at OHSU. Since last year, he and his team have received more than $9 million in funding from the National Institutes of Health to advance the potential of these so-called organ-on-a-chip devices in the fight against cancer. The latest grants target an aggressive form of prostate cancer that spreads to bones and a cancer of the bone that spreads to lungs. Bertassoni joins us to talk about this new technology and the promise he thinks it holds for the roughly 40% of adults in the U.S. who will likely develop cancer at some point in their lives.
My guest today is Alex Karnal. Alex is the co-founder and managing partner of Braidwell, a life sciences investment firm he built after spending 15 years at Deerfield Management. The frame we use throughout the episode is the health stack. Alex talks about how most of the diseases that will claim most of our lives are already addressable with medicines that exist today. We work through the five layers of what a defensive health strategy looks like, why GLP-1 medicines represent the first commercial proof that people are ready to be proactive about their health, and why PCSK9 inhibitors may ultimately be the more important drug class even though they get far less attention. We also get into the science and business of drug discovery itself — why most of the published literature that AI companies are training on cannot be replicated, what it would mean to have a truly agentic scientific lab running 24 hours a day, and why Alex believes we are now on a deterministic curve toward scientific superintelligence in biology. For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at colossus.com/subscribe. ----- Ramp's mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to ramp.com/invest to sign up for free and get a $250 welcome bonus. ----- Trusted by thousands of businesses, Vanta continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Visit vanta.com/invest. ----- WorkOS is a developer platform that enables SaaS companies to quickly add enterprise features to their applications. Visit WorkOS.com to transform your application into an enterprise-ready solution in minutes, not months. ----- Rogo is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit ridgelineapps.com. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Timestamps: (00:00:00) Welcome to Invest Like the Best (00:02:29) Intro: Alex Karnal (00:03:15) State of the Union: GLP1s and Life Sciences (00:07:01) The Health Stack Framework (00:12:49) Breaking Down the 5 Defensive Layers (00:21:18) GLP-1: What's Driving the Inflection (00:28:28) Diet vs. Drugs: Is Food Enough? (00:31:15) Barriers to Access: Complexity, Cost & Compliance (00:35:04) PCSK9: The Closest Thing to a Free Lunch (00:44:10) Alzheimer's & Neurodegenerative Disease (00:46:59) Cancer: Early Detection & New Treatments (00:54:49) Body Imaging & Diagnostic Trade-offs (00:56:31) How Drugs Are Discovered (01:02:39) AI in Drug Discovery (01:10:57) The Automated Lab of the Future (01:13:05) Peptides & Citizen Pharmacology (01:16:45) Alex's Background (01:28:25) Braidwell's Investment Approach (01:30:39) The Kindest Thing
In this episode, Meena Bansal, MD, FAASLD - System Chief, Division of Liver Diseases Director, MASH/NASH Center of Excellence, Icahn School of Medicine at Mount Sinai, discusses newly approved therapies for MASH and the growing impact of GLP-1 medications. She also shares insights on personalized treatment, early intervention, and the future of liver disease care.
In this episode, Meena Bansal, MD, FAASLD - System Chief, Division of Liver Diseases Director, MASH/NASH Center of Excellence, Icahn School of Medicine at Mount Sinai, discusses newly approved therapies for MASH and the growing impact of GLP-1 medications. She also shares insights on personalized treatment, early intervention, and the future of liver disease care.
In this episode, Dr. Aliyah Shafi discusses the transformative role of GLP-1 medications in diabetes care. Find out how they lower blood sugar levels and assist with weight loss. We cover treatment considerations and additional health insights to help you become familiar with these medications.
A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches
Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________This isn't medical advice — always talk to your doctor before making any health decisionsIn this episode of The Plus SideZ, we break down the latest GLP-1 news and what it actually means in real life.We're joined by Dave (Man on Mounjaro), who shares his firsthand experience coming off a GLP-1 after years on treatment, while we also unpack emerging research and what's coming next in this space.This conversation covers both data and lived experience, including:• What new studies say about stopping GLP-1 medications • Why benefits may reverse after discontinuation • Real-world weight regain, hunger, and metabolic changes • Mental health and brain-related effects tied to these medications • The difference between GLP-1 and GIP and why it matters • New and emerging medications being studied for neurological and metabolic conditions • Where treatment may be headed next beyond weight lossThis episode connects the dots between science, patient experience, and the future of obesity treatment so you can better understand what's happening now and what may be coming next.Whether you're on a GLP-1, considering one, or thinking about long-term use, this is a must-listen conversation.Guest Host: Dave Knapp @OnThePenPodcast______________________________________________________________________Join this channel to get access to perks: / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail! Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter, Producer TikTokInstagram
John Maytham is joined by Tulio de Oliveira, Professor of Data Science and Computational Thinking and Director of the Centre for Epidemic Response and Innovation (CERI) at Stellenbosch University. Professor de Oliveira is one of the world’s leading experts in genomics and data-driven health research and has been at the forefront of applying advanced computational tools to solve complex medical challenges. Afternoon Drive with John Maytham is the late afternoon show on CapeTalk. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic, and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30 pm. CapeTalk fans call in to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 to 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.
Let's say I take one type of immune cell from your blood, grow it in a lab and use a virus to cause changes in that cell so it recognizes cancer. Then I put it back in your body to … Temporary changes to T cells may empower new treatments for cancer and autoimmune disease, Elizabeth Tracey reports Read More »
Welcome to Resiliency Radio with Dr. Jill Carnahan, where today's episode challenges decades of conventional thinking about Restless Legs Syndrome (RLS). Dr. Jill is joined by Dr. James C. Anderson, whose groundbreaking research suggests that RLS may not be primarily a dopamine disorder—but instead, a problem of mechanical nerve compression in the lower leg. In this fascinating and science-driven discussion, Dr. Jill Carnahan and Dr. Anderson explore how decompression of the common fibular, superficial fibular, and tibial nerves may significantly reduce symptoms like burning, tingling, cramping, creeping sensations, and sleep disruption. This episode offers hope to patients who have failed dopaminergic medications and provides clinicians with deeper mechanistic insight into the root causes of RLS and peripheral neuropathy. ✨ Like, subscribe, and share to help more people discover innovative, root-cause solutions for chronic restless legs and sleep disruption.
When a two-year-old boy suffered a catastrophic injury that severed the connection between his skull and spine, doctors across Europe told his family there was no hope. His spinal cord was completely severed, and the injury was not considered survivable. But University of Chicago neurosurgeon Mohamad Bydon saw a possibility.In this episode of Big Brains, Dr. Bydon walks us through the extraordinary, multi-stage surgery at UChicago that not only saved the boy's life but helped him regain the ability to breathe, talk and move his fingers and toes. He examines the future of surgery for spinal cord injury patients—from minimally invasive surgery techniques to robotic surgery and AI to stem cell therapy—is even helping some paralyzed patients regain movement and even walk again after their injuries. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join us on February 18, 2026 at noon for our next episode of McGill Cares, a webcast series designed to support informal caregivers. During candid 30-minute interviews with leading experts, Claire Webster, Founder of the McGill Dementia Education Program, explores topics related to caring for a loved one who is living with dementia McGill Cares: New Treatments for Alzheimer's Disease Simon Ducharme, MD, FRCPC, is a neuropsychiatrist and a clinician-scientist at the Douglas Mental Health University Institute and The Neuro (Montreal Neurological Institute-Hospital). He specializes in frontotemporal dementia and the interface between psychiatric disorders and dementia. During this episode of McGill Cares, Dr. Ducharme will discuss new treatments and prevention strategies for Alzheimer's disease. He will provide information on a new medication, lecanemab, which has been shown to modestly slow cognitive decline in patients with early-stage Alzheimer's disease, explaining how it works, who might be eligible, and what the risks and side effects are. This free webcast will be available in both English and French. ____________________________ McGill Cares is supported by the Amelia Saputo Community Outreach for Dementia Care. This webcast series is an initiative of the McGill University Dementia Education Program, which is funded by private donations. To contribute or for more information about our program, please visit http://www.mcgill.ca/dementia. If you have any topics or questions that you would like us to address during our monthly webcasts, please email us at dementia@mcgill.ca.
Welcome to The Mental Breakdown and Psychreg Podcast! Today, Dr. Berney and Dr. Marshall discuss new treatments for ADHD, including some non-medication options that look promising. Read the article from Nature here. You can now follow Dr. Marshall on twitter, as well! Dr. Berney and Dr. Marshall are happy to announce the release of their new parenting e-book, Handbook for Raising an Emotionally Healthy Child Part 2: Attention. You can get your copy from Amazon here. We hope that you will join us each morning so that we can help you make your day the best it can be! See you tomorrow. Become a patron and support our work at http://www.Patreon.com/thementalbreakdown. Visit Psychreg for blog posts covering a variety of topics within the fields of mental health and psychology. The Parenting Your ADHD Child course is now on YouTube! Check it out at the Paedeia YouTube Channel. The Handbook for Raising an Emotionally Health Child Part 1: Behavior Management is now available on kindle! Get your copy today! The Elimination Diet Manual is now available on kindle and nook! Get your copy today! Follow us on Twitter and Facebook and subscribe to our YouTube Channels, Paedeia and The Mental Breakdown. Please leave us a review on iTunes so that others might find our podcast and join in on the conversation!
Welcome to The Mental Breakdown and Psychreg Podcast! Today, Dr. Berney and Dr. Marshall discuss new treatments for ADHD, including some non-medication options that look promising. Read the article from Nature here. You can now follow Dr. Marshall on twitter, as well! Dr. Berney and Dr. Marshall are happy to announce the release of their new parenting e-book, Handbook for Raising an Emotionally Healthy Child Part 2: Attention. You can get your copy from Amazon here. We hope that you will join us each morning so that we can help you make your day the best it can be! See you tomorrow. Become a patron and support our work at http://www.Patreon.com/thementalbreakdown. Visit Psychreg for blog posts covering a variety of topics within the fields of mental health and psychology. The Parenting Your ADHD Child course is now on YouTube! Check it out at the Paedeia YouTube Channel. The Handbook for Raising an Emotionally Health Child Part 1: Behavior Management is now available on kindle! Get your copy today! The Elimination Diet Manual is now available on kindle and nook! Get your copy today! Follow us on Twitter and Facebook and subscribe to our YouTube Channels, Paedeia and The Mental Breakdown. Please leave us a review on iTunes so that others might find our podcast and join in on the conversation!
As optometry moves into 2026, the profession is experiencing one of its most clinically rich and technologically diverse periods in recent memory. Reflecting on 2025 reveals a year defined not by a single breakthrough, but by meaningful shifts in how eye care professionals diagnose, treat, and communicate with patients. In Defocus Media's annual Optometry Trends […]
In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights the FDA's December 2025 approval of two innovative oral therapies that mark a significant step forward in combating this prevalent sexually transmitted infection. Dr. Fine discusses the first of these treatments, Zoliflodacin (Nuzolvence), a novel medication specifically developed for urogenital gonorrhea. Administered as a single oral dose, it offers patients a convenient and effective option. The second treatment, Gepotidacin (Blujepa), is a versatile drug initially approved in March 2025 for urinary tract infections (UTIs). Now, it has been authorized for urogenital gonorrhea treatment, requiring two oral doses for optimal efficacy. Throughout the episode, Dr. Fine provides insights into the clinical trials, mechanisms of action, and potential impact of these therapies on public health. He also emphasizes the importance of addressing antibiotic resistance in gonorrhea and how these new treatments may help mitigate this growing concern. For more information, listeners can refer to the FDA's official announcement and other resources provided below. Tune in to this episode to learn more about these exciting developments and their implications for the future of infectious disease treatment. Related Content: FDA Approves Two Oral Therapies to Treat Gonorrhea https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat- gonorrhea CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. https://ceitraining.org/
Looking 4 Healing Radio with Dr. Angelina Farella – Loss of sight, a major sense, may not always be predictable but may also be the first sign that something worse is going on. The smallest of our blood vessels are in the eye, visible only with special equipment and the skills of a great eye doctor. Clues are left within the eye, as other small-vessel disease is starting elsewhere. An astute eye doctor can see...
Looking 4 Healing Radio with Dr. Angelina Farella – Loss of sight, a major sense, may not always be predictable but may also be the first sign that something worse is going on. The smallest of our blood vessels are in the eye, visible only with special equipment and the skills of a great eye doctor. Clues are left within the eye, as other small-vessel disease is starting elsewhere. An astute eye doctor can see...
In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
WMAL GUEST: STEPHANIE HARIDOPOLOS (Chief of Staff and Senior Advisor in Surgeon General’s Office) on New Treatments and Diagnostics WEBSITE: HHS.gov/About/Leadership/Stephanie-Haridopolos BIO: Former Primary Care Physician Leading Health Policy Efforts Where to find more about WMAL's morning show: Follow Podcasts on Apple Podcasts, Audible, and Omny Follow WMAL's "O'Connor and Company" on X: @WMALDC, @LarryOConnor, @JGunlock, @PatricePinkfile, and @HeatherHunterDC Facebook: WMALDC and Larry O'Connor Instagram: WMALDC Website: WMAL.com/OConnor-Company Episode: Tuesday, December 16, 2025 / 7 AM HourSee omnystudio.com/listener for privacy information.
Summary In this episode of the Future of Dermatology podcast, Dr. Faranak Kamangar chats with Soroush Aboutalebi about his personal skin journey with a genetic condition called congenital ichthyosiform erythroderma, and the importance of community support through Camp Wonder. They discuss the challenges of managing skin conditions, the significance of compounding in dermatology, and the transformative experiences at Camp Wonder that help children build confidence and connect with others facing similar challenges. The conversation also touches on the future of dermatology, including exciting innovations in treatments and the role of dermatologists in patient care. Learn more about Camp Wonder: https://www.csdf.org/ Takeaways - Soroush Aboutalebi shares his journey with congenital ichthyosiform erythroderma. - Managing a skin condition can be challenging but also empowering. - Compounding medications have become less accessible in recent years. - Camp Wonder provides a supportive environment for children with skin conditions. - Building confidence is a key benefit of attending Camp Wonder. - Dermatologists play a vital role in the care provided at Camp Wonder. - Involvement in Camp Wonder can be through volunteering or donations. - The future of dermatology holds promise with new treatments and technologies. - Genetic therapies are on the horizon for skin conditions. - Community support is essential for individuals with skin diseases. Chapters 00:00 - Introduction to the Future of Dermatology Podcast 00:54 - Soroush Aboutalebi's Skin Journey 05:06 - The Importance of Compounding in Dermatology 08:08 - Camp Wonder: A Safe Haven for Kids with Skin Conditions 10:49 - Building Confidence Through Camp Experiences 13:46 - The Role of Dermatologists at Camp Wonder 16:16 - Getting Involved with Camp Wonder 20:14 - Future of Dermatology: Hope for New Treatments
The brother of the man who died in ICE custody in Clearfield County in August has filed a lawsuit against the federal government. And a deep dive: Women going through menopause have a new option for treating symptoms like hot flashes and night sweats: An FDA approved, non-hormonal medication is now available.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.
Feeding therapist, Kelly Komisaruk, chats about ARFID in kids and teens and the new treatment she's using to help them overcome anxiety about food.
Dr. Rahul Aggarwal presents emerging treatments for advanced prostate cancer, highlighting rapid advances in drug development. He outlines therapies targeting cancer cell surface proteins beyond PSMA, including CD46, B7-H3, and DLL3, and explains how antibody-drug conjugates deliver potent chemotherapy directly to tumors. He also discusses bispecific T-cell engagers designed to trigger immune attacks on cancer cells, including promising results from agents like Talquetamab. Aggarwal explores new isotopes such as actinium-225 for radioligand therapy, which may offer stronger and more durable responses than current treatments. He emphasizes continued innovation in targeting the androgen receptor, with drugs that degrade the receptor or block androgen production more effectively than existing therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40813]
Dr. Rahul Aggarwal presents emerging treatments for advanced prostate cancer, highlighting rapid advances in drug development. He outlines therapies targeting cancer cell surface proteins beyond PSMA, including CD46, B7-H3, and DLL3, and explains how antibody-drug conjugates deliver potent chemotherapy directly to tumors. He also discusses bispecific T-cell engagers designed to trigger immune attacks on cancer cells, including promising results from agents like Talquetamab. Aggarwal explores new isotopes such as actinium-225 for radioligand therapy, which may offer stronger and more durable responses than current treatments. He emphasizes continued innovation in targeting the androgen receptor, with drugs that degrade the receptor or block androgen production more effectively than existing therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40813]
Dr. Rahul Aggarwal presents emerging treatments for advanced prostate cancer, highlighting rapid advances in drug development. He outlines therapies targeting cancer cell surface proteins beyond PSMA, including CD46, B7-H3, and DLL3, and explains how antibody-drug conjugates deliver potent chemotherapy directly to tumors. He also discusses bispecific T-cell engagers designed to trigger immune attacks on cancer cells, including promising results from agents like Talquetamab. Aggarwal explores new isotopes such as actinium-225 for radioligand therapy, which may offer stronger and more durable responses than current treatments. He emphasizes continued innovation in targeting the androgen receptor, with drugs that degrade the receptor or block androgen production more effectively than existing therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40813]
Dr. Rahul Aggarwal presents emerging treatments for advanced prostate cancer, highlighting rapid advances in drug development. He outlines therapies targeting cancer cell surface proteins beyond PSMA, including CD46, B7-H3, and DLL3, and explains how antibody-drug conjugates deliver potent chemotherapy directly to tumors. He also discusses bispecific T-cell engagers designed to trigger immune attacks on cancer cells, including promising results from agents like Talquetamab. Aggarwal explores new isotopes such as actinium-225 for radioligand therapy, which may offer stronger and more durable responses than current treatments. He emphasizes continued innovation in targeting the androgen receptor, with drugs that degrade the receptor or block androgen production more effectively than existing therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40813]
Episode 316 hosts Meg McNeil (Director & Registered Nurse from Brisbane, Australia) & Bek McNeil (Director & Business Manager from Brisbane, Australia) In 'The Business of Injecting' episodes we host injectors and clinic owners to discuss all aspects of the business side of their clinic. We analyse their financial struggles and challenges, difficult decisions, friction points, staffing, hiring, firing and other topics relevant for aesthetic business owners. In Chapter 20 we discuss the success, challenges and future with two of the founders of Derm Haus. Our guests discuss their journey into the aesthetics industry, starting as a side hustle and growing it into a thriving business with two clinic locations and a team of 11. They share how they created a supportive work culture, handling the financials and logistics of a growing business, and the importance of using each team member's strengths. We also cover their strategies for marketing, patient retention, and the impact of word-of-mouth referrals. Our discussion wraps with insights into future plans for Derm Haus, including a focus on women's health and regenerative medicine, and the challenges of maintaining a successful business in a rapidly changing industry. 00:00 Introduction 01:20 Business of Injecting: Episode Overview 02:26 Meet the Derm Haus Team 03:38 Starting the Business: Challenges and Growth 10:20 Bringing Bek Onboard 17:46 Client Selection and Business Strategies 20:42 Managing Stock and Team Consistency 26:59 Creating an Employee-Centric Workplace 28:05 Deciding on New Treatments and Devices 32:05 Pricing Strategies and Financial Management 37:15 Staff Retention and Incentives 41:09 Marketing and Brand Strategy 45:08 Future Plans and Business Growth 49:26 Reflecting on the Journey and Final Thoughts SUBSCRIBE TO OUR PATREON FOR EXCLUSIVE PODCASTS, WEEKLY EDUCATIONAL CONTENT & JOIN OUR WHATSAPP COMMUNITY CLICK HERE TO BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS CLICK HERE IF YOU'RE A BRAND OR COMPANY & WANT TO WORK WITH US CLICK HERE TO APPLY TO BE A GUEST ON OUR PODCAST CONTACT US
The rationale, design, and mechanism of GABA aminotransferase and ornithine aminotransferase inactivators will be presented as well as in vitro and in vivo efficacy and pharmacokinetic results, toxicology studies, and a clinical trial with one of the inactivators.
Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments. We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab. Key topics covered in this episode: • Overview of the current treatment landscape and new data from ASCO 2025 • Common side effects associated with lurbinectedin and immunotherapy • Strategies for managing adverse events, including hematologic toxicities and liver function monitoring • The role of supportive care and palliative care in enhancing patient quality of life • Collaboration between community oncologists and academic centers for optimal patient care Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease. Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ #SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology
Dr Bill Nelson and Dr Michael Pishvaian discuss the targeting of KRAS mutations in pancreatic cancer to develop new treatment options for a disease that has been historically difficult to care for.
Kristy and Tiff discuss the new treatments they're seeing practices adopt these days and how to successfully start the process (if you want to). They touch on the best ways to gauge interest, training and implementation tips to start off, how to track results, and more. Episode resources: Subscribe to The Dental A-Team podcast Schedule a Practice Assessment Leave us a review Transcript The Dental A Team (00:01) Hello, Dental A Team listeners. We are so happy to be back here with you. We are recording today from the comfort of our own homes with the ACs blasting. I am about to bust out my fan. is on the charger right now. I don't know if you know this or not, but Kristy and I come to you from the sweltering desert of Phoenix, Arizona. And I have to say, I'm crazy. My boyfriend is like, it is hot. We're getting out of here. We're moving to Prescott. And one day I'm sure we will, but. I love where I live and every time I go travel to an office and I'm gone for like a week, I'll see two, three offices at a time. I come back in and just coming into Tempe on that plane over in the mountains, you can see the Buttes, you can see South Mountain, you can see the city and just like the buzz of it all makes me so incredibly happy every single time. I love where I live. I cannot at this point in my life imagine living anywhere else. So when I say that out loud, People think I'm crazy. And I'm like, listen, it's beautiful here. My best friend, bless her heart, she's like, Tiff, it's brown. It's all desert. And I'm like, it's not. Do you see these colors, like the saguaros and the pink flowers that bloom and the yellows? And like, I don't know, Kristy, am I crazy? Or what are your thoughts? You came back to Arizona. So obviously, there's something to be told about that. DAT Kristy (01:25) It's too funny that you say that because it's so true. I'm you know when I moved to Idaho everybody's like Arizona it's a desert and I'm like but there's desert here. I have to agree the Arizona desert is much prettier. ⁓ Southwestern Idaho is very deserty and we're talking brown. There's where the brown is but Arizona desert is very beautiful. Even this time of year like come on Palo Verde's aren't brown they're green. The Dental A Team (01:35) Yeah. Yeah. Bye. Right? Literally in their name, right? Palo Verde. My boyfriend always says, yeah, Arizona is like so inventive, the green stick. And I'm like, well, it's green. It is green, okay? That's our state tree and it's green. Yeah, I agree. I agree. I just think it's beautiful. And there's nothing like a desert rain. I know that sounds so cliche. Everyone says it, everyone hears it, but I swear to you, the smell in the desert after a good rain or even a light sprinkling is magical. There is something about it that just changes the composition of your body and you become a much happier individual. just, can't be, you can't be angry in the desert rain. So. DAT Kristy (02:33) agree with you Tiff and if you and I can figure out a way to bottle that stuff I've always said we'd be millionaires. The Dental A Team (02:39) Yeah, well, you know, I just, my friend just told me this a couple months ago. There's actually a bush out there. I need to just take a picture of it and figure out what it is. We were hiking one day. There's a bush out there that you, when you pick the leaf and you like put it between your fingers, it smells like the desert rain. I'll find it. Yeah, I'll find it and take a picture. I don't know what the bush is, but I'll find it and take a picture and Google it so that we can, we could bottle it. My point there. Yeah. I actually had a friend in town. DAT Kristy (03:02) Yeah. The Dental A Team (03:06) Um, he lives in North Carolina and he was visiting and he was like, I'm taking some of this home so that other people can smell it. Cause it is incredible. And I'm like, yep, that's what Arizona desert rain smells like. So anyways, everybody who wants to come visit, we are here for it. We aren't taking any new visitors like to stay. I'm just kidding. You can move here. It's just, it's just getting crowded, you know, but visitors are welcome. Come. share in the heat. I know most people come in the month of February for the Waste Management Open and you just let us know when we're here and Kristy and I will pop over and say a little hello to you. So Kristy, getting on to business, I love talking about Arizona and I would do it forever, ⁓ but we're kind of rounding out the year right now. We're heading into quarter four. This is the time of year I'm like, well, we can still make massive movements, we can still make massive changes and hit those goals, but really we need to start thinking about what are we doing ⁓ after these goals are hit. So lot of people don't think about the next year, which is 2026 until December, but I'd like to start talking about it here in August. So one of those pieces, Kristy, I really wanted to chat today about offices that we've seen implement new treatment. And I know right now, ⁓ fillers, Botox, I've seen a ton of practices doing like facial aesthetics and the lasers and I don't even know what they're called the ones and like all of these amazing things and takes me back to when I was ⁓ working in office gosh when I first started I was like 19 and my doctor's like where are those paraffin wax things can we get those and I was like you're crazy we are not a spa like we're not doing paraffin wax for our patients I have enough to do chair side, have enough to clean up, we're not doing this, right? But he really wanted it and so we did at least, we did warm towels. So it's like, I can handle warm towels, it's all you got. But now, there is really like this spa aesthetic feel to a lot of dental practices. And I know there's plenty of us out there that are like, no, not doing that. I am a dig my heels in kind of girl. So I dig my heels in until the very end. But I'm kind of getting on board with it. I kind of like it. And it's adding a different sense and a different value. And honestly, I love marketing and it's adding a different marketing avenue because it's a different demographic of people who can come for the aesthetic side and see, I love these people. Let me switch my dental as well. They may not, that's okay. They may love their dentist. But if you can come to one place and get multiple things, that's kind of cool. So, Kristy, I just wanted to chat a little bit about some of the things that we've seen. We've worked, you guys, just so you know, we worked with a ton of practices on adding aesthetics. Botox fillers, ⁓ implants, just like simple single tooth implants, multi-tooth implants, all on fours. Gosh, what else? Orthodontics, making sure that the marketing is there, making sure that the treatment coordinating aspect is there, making sure that case acceptance is working, the schedule is working, the block scheduling. We have helped implement this in so many practices. So as we're talking today, just know we're speaking from that implementation experience and what we've seen really work for practices. from our experience working one-on-one with doctors. If you're someone who's looking to implement new products or new services in your practice and you're not really sure on the how-to, please reach out. We would love to help you on a one-on-one basis. Hello@TheDentalATeam.com. Again, we have a ton of experience in this. have five experienced consultants ready to work one-on-one with you. ⁓ Kristy, Monica, and Trish are... freaking incredible you guys. I have just seen them move mountains for clients in very short amount of time. if you are ready to take that step, let us know. Hello@TheDentalATeam.com. But Kristy, I know you've had a lot of clients. You've actually had, you've had some fun clients that I can think of off the top of my head that are kind of fresh and new and starting out. And I know one in particular I can think. probably is this like go-getter wants to add everything, wants to take all the CE, wants to implement everything and wants to just run with it. And then you've got some others that are like, I'm going to like take my time. I'm going to buy it my time. I'm to take the CE. Maybe in a couple of years, we'll be able to implement it. Like there's like such drastic differences there, but what kind of ⁓ procedures have you seen implemented recently? And what do you feel like your clients are doing really well? to implement them within their practice with your support. DAT Kristy (07:45) Well. like you, the med spa thing has really taken off in dentistry. So adding in the Botox, the laser ⁓ and sleep, even for little kiddos, the tongue ties has been an area of exploration. with that being said, Tiff, think first and foremost, yes, you're right. I have one client that's kind of a go getter and and honestly him bringing the energy has worked really well for him because his excitement is driving it, right? But one thing that I would say in the very beginning, if you're exploring this and you aren't that go getter, energetic, I'm going to do this attitude and you're kind of thinking about it, start to take a pulse with your patients. know, explore, hey, if we offered this service, is this something you'd be interested in? See if people are interested in it because you may be leaving room on the table, right? And maybe you'll find out they're not interested and it will drive you in a different direction But with that being said, like I said take a pulse of your own patients, but I also doctors recommend that you ⁓ Get your admin team ⁓ Keeping a list of things that patients are calling in and asking for and they have to say no we don't do that because that's an area of opportunity that perhaps if you have a hundred people calling and asking The Dental A Team (09:10) That's a great idea. Yeah. That's a great idea. I have never in my life thought of that. That's beautiful. I love that you said to ask the patients themselves as well. If I started offering this, is this something you'd be interested in? And that one's kind of an easy one when it comes to like Botox and things like that, because you can tell when someone has utilized that procedure before. So I've even had doctors say, where are you going for your Botox? Like, do you like where you go? Are you happy there? What are they doing well that keeps you coming back? even as far is to ask what they're paying because it really helps them to figure out. how they can generate that within their own practice based on a scale of like, know, chatting with a couple of different patients, because you really can tell fillers as well. And all of that stuff, you guys, to be redone at some point. So I think that's a great idea. apnea is huge. I think the kiddo stuff is massive. I have a couple of doctors, couple of doctors, but then also I have a GP doctor that does a ton within the lip tie, the sleep apnea, all of those pieces for the toddlers and children. She's so passionate about it that her team is behind her as well on it. So I think that's a really good point. And I think, Kristy, something you touched on was that passion and how excited that specific doctor we're thinking of is about everything he does, everything he does he's excited for. And so I just feel like walking into his practice, you're just amped up. Like the energy's got to be so high. But for... everyone no matter what anytime you go take a CE, anytime you have an idea, anytime you're like I want to implement this and you go get trained on it, I think the biggest missing piece that I've always seen myself as a consultant and then myself even as a dental assistant or for an office is that information lapse between you taking the course and coming back with the information and that ⁓ I get from a business standpoint and a doctor's standpoint, it's hard to take your team to the CE with you. And sometimes it's not even offered to bring your team. So I get that, but that's where training comes into play. And I think that's where having someone on your side, a coach and a consultant, someone who's working hand in hand with the team who really can help create protocols, who can help with the verbiage because you're over there implementing. And I don't know, Kristy, if you've ever experienced this, I remember my doctor, he would get so deflated. because he'd go do this thing, he'd be rammed up sleep. He wanted to sleep so badly and I hope to this day that he's doing it, but it was so difficult and we didn't get the training, we didn't get the courses, he was training us which was great, but it was like also we are doing everything we were doing before you took this course. So the space for me to learn how to add this, for me to take the time out of my day, to implement this just isn't always there. And so the space to do the training is sometimes lacking if you can't take your team with you. So I know I've got a practice that I've helped a ton with sleep just in general at their practice because they needed the protocols put in place, but they didn't have the time to even sit down and type them. So it was like, We're going to do this together real quick. Our tips got these ideas. We've got templates that we utilize with our clients that we're like, hey, these are my ideas. And we go back and forth. And we figure out what's working, what's not working. And Kristy, I know you've done that too. What have you seen work really well with practices for that training and implementation? DAT Kristy (12:57) It's kind of funny because the ways you're talking I'm thinking of a client right now that literally just went she did take her team to Vegas for clear liner course and Thank goodness. were blessed to go right because you're you're right getting the whole team behind them and the energy coming back in is huge the energy really does propel the momentum as you're Trying to ramp up and to your point not everybody can take the whole team So so I get that yet if you can get one or two chances to go and help you wonderful. If not, would definitely recommend coming back and having the conversation and have doctors speak to their why. You know, why do they want to implement this? What is their vision for it? And then create benchmarks. Like how will we implement this and what can we do? So if we want to do more clear aligners, what is The Dental A Team (13:37) Yeah. video. DAT Kristy (13:56) something we can do every day to help that outcome, right? Is it add one more scan to a patient? You know, get those commitments from team and buy in and then have fun with it. We're always talking about the sprinkles and adding the fun. So find a way to gamify it. And if I do this action every day, it's going to create a better chance of my outcome, right? The Dental A Team (14:00) Yeah. Mm-hmm. Yeah, yeah, and to that point, you're then tracking your results, right? Which is something that we have all of our practices tracking their results consistently for that reason, because we want to see the things that you're doing every day. Are they creating the result that you wanted? Are we moving closer to the goal that you were set after? Or are we moving further away from it? Because then we can see what we want to tweak or change or what needs to be added. And then again, to your point as well, what's one thing that we can add? A lot of times we come in with all of the things and it's like, that's too much and we can't process it all. So if you do that, like one thing, so for sleep apnea or Botox or any of those spaces or though it's like, what's one thing you would change aesthetically if you had the opportunity? Like what's one question? You can start asking every patient that walks through your door. Do you find yourself waking up a lot at night? Do you find yourself, know, do your partner say that you're snoring? Do you have a hard time falling asleep? Do you have a hard time waking up? What are the key factors? What's one question, two questions you add onto it? How can we layer this and stack to get things done? And like you said, maybe we're taking one more scan today than we took yesterday. We're gamifying it, we're tracking the results, and we're making sure that it's fitting. And that's something that I think as consultants, we've been able to really help teams get excited about. and really be able to help them break it down because for doctors, for our visionaries, it's sometimes difficult for a visionary to see the path. They see the end result. They see what it is that they're after. They see the dream and the finality. We have to take it layers backwards and say, how do we get there? The visionaries have a hard time figuring out how we're going to get there. And when they're the only ones who are trying to figure that out or there's no one on the team that's like, okay, I got it. I will figure it out from here. That's where the consultants come into play or training office managers to see that space to say, okay, what are the steps it's going to take to get there? And how do we incrementally layer and add onto those steps to ensure that we do? So, Kristy, I think you're hitting some massive spaces there. with the tracking the results, the just one thing and making sure that we are training the team as we can. I also think don't wait too long. If you've gone to a course and you've learned something, you need to start practicing it because you learned it. And then if you're waiting a year to implement it, you're going to need to go back for a refresher course because you haven't been doing it. And I've seen that happen. I don't know if you have. I've seen that happen, especially with like Botox, where they go get the training, but they're just like dragging their feet, probably out of fear and actually implementing it. And then they're like, well, shoot, I need to go get a refresher course because I haven't done it since I did it at my training. Have you seen that too, Kristy? DAT Kristy (17:27) Absolutely. I love that you mentioned that because I think one realm where we're really good at this if you think about it is ⁓ Milling same-day crowns because they force you to find patients, right? They're like, okay have your patients lined up because we're gonna do it in those other realms We don't necessarily do that. So a component that I think we miss a lot is we plan the CE we schedule it we go the course But we didn't block out time to meet with team coming back, right? The Dental A Team (17:36) Yeah. ⁓ Yeah. DAT Kristy (17:57) So make sure that time dedicate the time to make sure it happens and Hey, let's line up the patients. Let's get them in the chair and start because you're right Otherwise, we just get back into routine and it's gone to the wayside and you know See is wonderful and it's all knowledge. But unless we're interpreting it into something It's just money spent right? Yeah The Dental A Team (18:22) Agreed. Yeah, agreed. And it makes me think of two of ⁓ Like you said, they tell you to have patients ready for the crowns, but same thing for implants, right? Same thing for Botox, same thing for any of those, but implants especially. I always tell doctors, before you go to the course, I say take inventory, look at how many outgoing referrals you had to oral surgeons. How much revenue did you feed oral surgeons in your area of that thing that you're going for? Because they have had practices in areas of their city that it was like it didn't make sense financially to implement the thing because they weren't getting it in their doors, right? They were a younger demographic, they were college demographic, and they really just weren't getting a lot of need for the implants or for whatever it was that they were looking at. And so they actually decided, you know what, like that was just, there's so much that we see that we're supposed to do. ⁓ like all on four, all on X. Like there's so many GP dentists that are like, well, I just felt like I heard that that was what was going to change my life forever. And I'm like, yes, in a lot of ways, it's really hard. So don't do things just because it's what you're supposed to do. And it's like the next best up and coming thing. Cause I have seen doctors who have taken inventory and they're like, actually, like I was going to do it because I thought I needed to, but I don't think my patient demographic shows me that I need to. I may actually focus in on this and they switched their CE focus completely because they saw the need wasn't there and for me that's massive because now you're you are getting an ROI on what you're doing. Now for a lot of dentists they want to learn the thing because they want to know it and that's totally cool. don't I don't I have no ifs, ands, or buts about it but just make sure you know what you're getting into and then like Kristy just said I love that idea of making sure you've got people lined up to get the service. once you come back. And it's an easy conversation. It's not, I'm going to go get trained on implants. And so when I come back, I'd love for you to be one of the first people I place an implant on. That's uncomfortable, right? But it's just like, hey, I don't have the tools for this right this second. ⁓ You can go to an oral surgeon if you want it sooner, but I am going to be equipped with those tools here in the next six months. I'd be happy to revisit this with you at your next re-care or call you as soon as I get the stuff in. Same statement, different words. so vulnerability on one hand. If it's family, like shoot, I've had plenty of doctors that's like, hey, I'm testing this on you and you're getting it for free. Or I'm testing it on you and you're gonna pay for the lab fee, like fine. whatever, but patients maybe be a little bit more tactful with. But Kristy, I think those were some great points. Those are all wonderful things that I've seen you help doctors implement. I've seen Dana, Kristy, or Trish. I've seen all of you guys. Monica, know she's done it too. We've all implemented on some level some of these systems and protocols with practices for things that feel really hard when you're in it. The great part about consultants, I'm not attached to it, you guys. Kristy's not attached to it. We're attached to you seeing results and we're going to bird's eye view it and see where the missteps are happening, where the gaps are that can be filled to create a different result because Kristy's not emotionally attached to it. So they do really, really well. Kristy, Trish, Monica, Dana, all of them do really well at being able to see those gaps and see how you as a team can fill them and then train you guys on how to fill them. Our job is not to do it for you because then I'm not teaching you anything, right? Kristy is not, she becomes your regional manager and that's not what we signed up for. But what her job is to do is to show you the path, train you how to do it, watch those benefits, you reap those benefits at the end. So we're excited to help you guys. Kristy, I know you're excited. You love implementing and Kristy loves nothing more than finding the money, finding the money, finding the production and helping you implement structures that really work to make a difference in your practice. Kristy, thank you for your words of wisdom today. Those were fantastic. think my biggest nugget today is the idea of duh. have people lined up and ready to go for whatever it is prior to you ever going and getting the course. And I think as I say that, Kristy, there's a lot of protocols and a lot of training that can be done prior to the CE to get your team ready too. Because otherwise the team's just upside down trying to figure it out. But those protocols and things can be put into place before you actually get trained to place and plan. So Kristy, thank you for being here with me today. ⁓ Everyone, I hope you took some solid nuggets from this and you can see how beneficial this can be. Drop us a five star review below. We'd love to help you. Hello@TheDentalATeam.com. We can't wait to hear from you guys. Thanks.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/personalizing-care-identifying-the-right-patients-for-new-treatments-10268SummaryDr. Genevieve Neal-Perry and Dr. Andrea Singer focus on practical strategies in the personalized management of menopausal vasomotor symptoms (VMS). The discussion covers the importance of routine and individualized screening for VMS, with attention to healthcare disparities and the diverse ways menopause is discussed and experienced across populations, before covering patient selection criteria for newer non-hormonal treatments.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesIntegrate routine and individualized screening methods to identify patients with menopausal VMS, with attention to healthcare disparitiesIntegrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preferenceThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer. --- This podcast is supported by an educational grant from UroGen Pharma. --- SYNPOSIS The doctors break down the nuances of defining this risk category and the clinical gray zones that complicate treatment decisions. Dr. Herrell shares her patient-centered approach to surveillance and therapy, and introduces promising new agents, including Anktiva, UGN-102, and the gemcitabine-releasing TAR-200 "pretzel" device. The discussion also highlights how advances in molecular profiling are reshaping care strategies.This episode underscores the urgent need for clearer guidelines and continued innovation to improve outcomes and quality of life for patients with this nuanced disease subtype. --- TIMESTAMPS 00:00 - Introduction02:03 - Defining Intermediate Risk Bladder Cancer06:12 - Intravesical Therapy Options08:47 - Quality of Life and Patient Counseling10:18 - New Treatments on the Horizon12:56 - Practical Tips for TURBT Recovery17:03 - In-Office Procedure Management21:38 - Managing Symptoms and Quality of Life31:50 - A Note on Smoking Cessation33:37 - Conclusion and Future Directions
The Real Truth About Health Free 17 Day Live Online Conference Podcast
Dr. Theodore Henderson is an MD. PhD, Founder, CEO and Medical Director of Neuro-Luminance, who brings decades of clinical experience in psychopharmacology, neurobiology, infrared light therapy, and neuroimaging to the successful treatment of brain disorders. Dr. Henderson and his team specialize in treating patients with depression, concussion, brain injury, PTSD, Chronic Fatigue Syndrome, Parkinson's Alzheimer's, and ADHD. He is also the author of the recently published book titled “Brighter Days Ahead: Leaving Depression Behind Through Innovative New Treatments” which is an excellent and easily readable introduction for people of every walk of life to understand the concepts as well as the benefits and healing power of infrared light therapy. In this informative, positive, hopeful, and also entertaining episode, Dr, Henderson skillfully explains exactly how the brain changes as a result of depression, traumatic brain injury, Long COVID, chronic fatigue syndrome, and other brain disorders. He describes the revolutionary new treatments that activate the brain's own ability to repair itself. He has a knack for describing complex brain conditions and neurological function in great detail and in terms that are easy to understand, and he does it with a sense of humor as well. Download this fascinating episode to hear Dr. Henderson's story and discover how these groundbreaking new treatments can give hope and healing to people suffering from brain disorders and neurological dysfunction, and please share this positive message of hope and healing with your friends, family, and anyone you know who can benefit from this remarkable technology. Connect with Dr. Henderson: https://neuro-luminance.com/ https://www.facebook.com/LuminanceBrainHealth https://x.com/neuroluminance?lang=en&mx=2 https://www.youtube.com/@NeuroLuminance?app=desktop https://www.linkedin.com/in/theodore-henderson-md-phd-98201318/ https://www.youtube.com/watch?v=zdFstQSR_A4
In this episode of The Egg Whisperer Show, Dr. Jenna Turocy is joining me to talk about new treatment options for recurrent implantation failure. Recurrent implantation failure (RIF) is determined when embryos of good quality fail to implant following several in vitro fertilization (IVF) treatment cycles. The good news is that there is treatment for this, and Dr. Turocy has been researching it. The types of treatments that Dr. Jenna has studied include:
Mandy talks about how expensive it is to replace the Ford F-150 Lightning truck battery is, she spoke with a young man with a fatal disease who is advocating for Right to Try new meds, Rich Guggenheim with Gays Against Groomers pops on for an update, Hamas wants Palestinians to starve rather than take aid from a group that MAY be associated with Israel, and the Plum Creek Garden Market team visited to talk about glow in the dark petunias.
Dr. Andreas Walther is a senior researcher for science and teaching at the Department of Clinical Psychology and Psychotherapy of the University of Zurich and clinical psychotherapist with the outpatient clinic for Cognitive Behavioral Therapy and Behavioral Medicine of the Psychotherapeutic Centre of the University of Zurich. Andreas discussed the journey to his work focused on developing a treatment for men experiencing masculine or masked depression. He mentioned his father's struggle with depression and a serendipitous meeting with a graduate school advisor who needed a student to conduct research on men. Andreas' initial work was focused more on the effects of testosterone on mood in men, but increasingly his work led him to also integrate the investigation of masculinities into his research. He is currently conducting a clinical trial that involves the investigation of gendered depression in men. We discussed what this treatment looks like compared to a standard treatment for depression. D83
There's a care model for schizophrenia that actually works—why isn't it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.Also discussed:The first novel schizophrenia drug in over 50 years (Cobenfy)Why clozapine is underused—and how that may finally changeThe potential of brain imaging and biomarkers in psychiatric treatmentWhat a real community mental health system looks likeWhy trust, not just treatment, is essential for recovery
TODAY ON THE ROBERT SCOTT BELL SHOW: Universe 25 Experiment, David Rasnick, Kala Mandrake, Caltha Palustris, Realtime Vax Injury Tracking, New Treatments for Measles, Gold for Groceries, Bayer Glyphosate Immunity, Real Dino-Skin Purses, Question of the Day, and MORE! https://robertscottbell.com/universe-25-experiment-david-rasnick-caltha-palustris-digital-vax-injury-tracking-new-treatments-for-measles-gold-for-groceries-bayer-seeks-glyphosate-immunity-real-dino-skin-purses-question/
TakeawaysMASH is a significant obesity-related complication.Semaglutide shows promise in treating MASH.Weight loss is crucial for improving liver health.Bariatric surgery remains the most effective treatment.The Essence trial indicates a 63% resolution of NASH.New medications are being developed for obesity treatment.Early intervention is key to preventing severe liver damage.Accessibility of medications is a major concern.Comparative studies are essential for evaluating new treatments.Future treatments may include innovative delivery methods.Chapters00:00 Introduction to MASH and Semaglutide Study04:29 Understanding Metabolic Dysfunction and Its Implications08:02 Essence Trial: Semaglutide's Impact on MASH12:58 Comparative Analysis of New Treatments for MASH17:30 The Future of Obesity Treatment and Drug AccessibilityJoin Vineyard - Dr. Spencer's online clinicSee the study
In today's episode, I was very excited to sit down with Dr. Ilana Gurevich to discuss the latest, most effective approaches to GI conditions. We explore the usage of sulfur for the gut, the role of the mitochondria in the body's overall health, treating parasites, as well as SIBO and Candida. We'll also share recommended protocols for each condition. Listen now!
© 2020-2026 Ivy Podcast Discovery LLC
